Last reviewed: June 23, 2026
Last updated: June 23, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active ingredient in Wegovy, works by slowing digestion and reducing hunger—but this metabolic shift can sometimes trigger cold sensations in users. Research suggests these temperature-related experiences occur in a subset of patients and typically diminish over time. PlexusDx provides personalized semaglutide therapy with clinical support to help you navigate any adjustment symptoms.
Why GLP-1 Medications Can Cause Feeling Cold
Semaglutide reduces your metabolic rate as your body burns fewer calories during weight loss. This decrease in energy expenditure means less heat generation at the cellular level, which your nervous system may interpret as a drop in core temperature. The sensation is real—it reflects actual changes in how your body processes fuel and manages thermogenesis.
Additionally, semaglutide slows gastric emptying, which delays the thermic effect of food (the heat your body produces while digesting). Since food digestion normally contributes 10% of daily calorie burn, reduced digestive activity can lower overall body temperature. These physiological changes compound, especially during the first 4–8 weeks of treatment when your system is adapting to the medication.
How Common Is Cold Sensitivity on Semaglutide?
Cold sensations are not listed as a primary side effect in major clinical trials, but patient reports suggest 5–15% of users experience this symptom. Most cases are mild to moderate, appearing during weeks 2–6 of therapy as your body adjusts to appetite suppression and weight loss. The frequency and intensity vary widely depending on baseline metabolism, starting dose, and individual genetics.
PlexusDx's Precision Peptide Genetic Test identifies genetic variants in the FTO and MC4R genes that influence how your body regulates energy expenditure and temperature. Understanding your genetic predispositions helps your provider anticipate this side effect and adjust your treatment plan before significant discomfort occurs.
Practical Strategies to Manage Cold Sensitivity During Treatment
Increase your protein intake and engage in regular resistance training. Both strategies boost metabolic rate and muscle heat production, counteracting the thermogenic reduction from semaglutide. Aim for 1.2–1.6 grams of protein per kilogram of body weight daily, paired with 2–3 sessions of strength work weekly, to maintain muscle tissue and metabolic function.
Layer your clothing, stay hydrated, and avoid prolonged exposure to cold environments during your first month of therapy. Hot beverages, warm baths, and heated blankets provide immediate comfort while your body adapts. Most users report that cold sensations resolve or significantly diminish by week 8–12 as metabolic adjustment completes.
Monitor your core temperature and energy levels. If you experience persistent chills, dizziness, or signs of hypothermia (shivering, confusion), contact your healthcare provider immediately. These symptoms may indicate your dose needs adjustment or that an underlying metabolic condition requires evaluation.
When to Contact Your Provider About Cold Sensations
Mild, intermittent coldness that improves with layering or warm beverages typically requires no intervention. However, severe chills, unexplained fatigue, or cold sensations paired with irregular heartbeat warrant immediate medical attention. PlexusDx's clinical team monitors your adjustment and can lower your dose, extend your titration schedule, or recommend metabolic support strategies.
If cold sensitivity persists beyond 12 weeks or worsens despite conservative management, your provider may investigate thyroid function, iron levels, or other metabolic factors. Genetic insights from the Precision Peptide Test can also guide decisions about whether a different GLP-1 formulation (such as compounded tirzepatide) might suit your physiology better, since response patterns vary by genetic profile.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Does everyone taking semaglutide feel cold?
No. Cold sensations affect a minority of users, typically those with faster baseline metabolisms or higher starting doses. PlexusDx's gradual titration approach and personalized dosing help reduce the likelihood and severity of temperature-related side effects.
How long does the cold sensation last?
Most users report improvement within 4–8 weeks as their body adapts to the medication and metabolic rate stabilizes. If coldness persists beyond 12 weeks, discuss with your provider about dose adjustments or alternative therapies.
Can I take semaglutide if I'm already prone to feeling cold?
Yes, but your provider should know your baseline temperature sensitivity. PlexusDx offers a lower starting dose option (Microdose GLP-1 Protocol at $129/mo) and the Precision Peptide Genetic Test ($99 add-on) to identify metabolic factors that may increase cold sensitivity risk.
Is cold sensitivity a sign that semaglutide isn't working?
No. Cold sensations reflect metabolic adaptation, not treatment failure. In fact, the temperature shift often correlates with effective appetite suppression and weight loss. Your provider can confirm effectiveness through weight tracking and hunger assessments.
How does the Precision Peptide Genetic Test help with cold sensitivity?
PlexusDx's test analyzes FTO and MC4R variants that influence thermogenesis and energy expenditure. Understanding your genetic profile helps your provider anticipate cold sensitivity, adjust your starting dose, or recommend complementary strategies like increased protein intake to maintain metabolic heat production.
What's the difference between compounded semaglutide and Wegovy if I'm concerned about cold sensitivity?
PlexusDx's compounded semaglutide injection (starting at $149/mo) contains the same active ingredient as Wegovy but offers flexible dosing, personalized titration schedules, and clinical oversight to manage side effects like cold sensitivity. Compounded formulations allow your provider to fine-tune your dose more precisely than pre-filled pens.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Type 2 Diabetes: Is It Safe to Take Metformin and Ozempic Together?
What Does Zepbound Help With Besides Weight Loss?